Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-CENK and N-803 in Locally Advanced or Metastatic Solid Tumors
NCT04898543Phase 1Active, not recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Jun 2021
- Primary completion
- Feb 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of M-CENK in solid tumor (2 cohorts), sponsored by ImmunityBio, Inc. Primary endpoints: Treatment-Emergent Adverse Events and Serious Adverse Events related to apheresis at 1 week, Number of participants with clinically significant laboratory tests related to apheresis at 1 day and 4 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
M-CENK
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04898543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898543.